International Stem Cell - A strong 2018 for the commercial business
International Stem Cell (ISCO) reported strong FY18 revenues of $11.1m, up 48.7% compared with 2017 mainly due to the biomedical business, which had revenues of $9.3m, up 78.4% year-on-year. The profitability of the biomedical business continues to improve as well, with operating income of $3.3m, up 78.2% compared with the previous year. The company has also reported that the 12-patient Phase I trial of ISC-hpNSC in Parkinson’s disease (PD) is now fully enrolled with complete data expected in H120.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.